- Home
- TRS vs IMCR Comparison
TRS vs IMCR Comparison
Compare TRS & IMCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TRS | IMCR |
|---|---|---|
| Founded | 1986 | 2008 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.6B |
| IPO Year | 2004 | 2016 |
Fundamental Metrics
Financial Performance| Metric | TRS | IMCR |
|---|---|---|
| Price | $39.96 | $34.23 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 10 |
| Target Price | $41.50 | ★ $66.33 |
| AVG Volume (30 Days) | 462.7K | ★ 718.5K |
| Earning Date | 04-30-2026 | 05-07-2026 |
| Dividend Yield | ★ 0.44% | N/A |
| EPS Growth | ★ 400.00 | 30.39 |
| EPS | ★ 21.40 | 0.25 |
| Revenue | ★ $645,720,000.00 | $249,428,000.00 |
| Revenue This Year | $5.42 | $14.57 |
| Revenue Next Year | $4.27 | $8.21 |
| P/E Ratio | ★ $1.90 | $139.72 |
| Revenue Growth | N/A | ★ 43.05 |
| 52 Week Low | $30.43 | $27.56 |
| 52 Week High | $45.43 | $40.71 |
Technical Indicators
Market Signals| Indicator | TRS | IMCR |
|---|---|---|
| Relative Strength Index (RSI) | 40.27 | 63.55 |
| Support Level | $39.24 | $30.92 |
| Resistance Level | $41.84 | $36.33 |
| Average True Range (ATR) | 1.33 | 1.62 |
| MACD | -0.33 | 0.20 |
| Stochastic Oscillator | 4.80 | 71.75 |
Price Performance
Historical ComparisonAbout TRS TriMas Corporation
TriMas Corp designs, develops and manufactures a diverse set of products for the consumer products, and industrial markets . The company operates through two segments namely: The packaging segment manufactures and distributes closure and dispensing systems. The specialty product segment manufactures and distributes steel cylinders, wellhead engines, compression systems, industrial sealing, and fasteners. The packaging segment generates majority of its revenue.
About IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.